Exchange rate movements had a negative effect of 0.1 percentage points. In the fourth quarter of 2016, Company sales were €8,867 million, up 3.3% on a reported basis. Investor Relations: (+) 33 1 53 77 45 45 - E-mail : - Media Relations: (+) 33 1 53 77 46 46 - E-mail : Mobile app: SANOFI IR available on the App Store and Google PlayĢ016 fourth-quarter and full-year Sanofi sales Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER (6). The consolidated income statement for Q4 20 is provided in Appendix 4 and a reconciliation of business net income to IFRS net income reported is set forth in Appendix 3 (2) changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 11) (3) Merial information is provided in appendix 5 (4) See page 8 (5) 2016 Business EPS was €5.68. Business net income is a non-GAAP financial measure (see Appendix 11 for definitions). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement.
Separately, we recently advanced five new molecules into registrational studies." At the same time, we completed the filing of our breakthrough innovation Dupixent ® for the first indication, atopic dermatitis, in the U.S and Europe. Our streamlined organization started to deliver and supported a stronger financial performance than initially anticipated. We successfully closed the Boehringer Ingelheim asset swap, lifting us into a leadership position in Consumer Healthcare. "2016 was a busy year for Sanofi as we progressed on our 2020 strategic roadmap. Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
0 kommentar(er)
